Industry group says FDA botched COVID-19 convalescent plasma guidance
pharmaphorum
AUGUST 27, 2020
Bioindustry association MichBio says the FDA’s labelling requirements for COVID-19 convalescent plasma (CCP) – which were published alongside the emergency use authorisation – could lead to “hundreds, if not thousands, of in-date, ready to transfuse CCP units across the country being rendered unusable.”.
Let's personalize your content